The Bethlehem, Pennsylvania-based OraSure Technologies, Inc (NASDAQ:OSUR) got approval for the primary at-home HIV test that allows people find results without using a doctor or laboratory.
The agency reported in a statement on Tuesday that the Food and Drug Administration cleared the saliva test that offers results within 20 to 40 minutes and would be sold without an instruction.
Caroline Corner, a senior analyst with McNicoll, Lewis & Vlak in New York stated before the agency’s announcement that the sales may reach $20 million coming year supposing a $40 price tag for the product from OraSure.
Almost 250,000 people at risk of HIV are not tested. Advisers to the agency who supported the gadget May 15 reported that it may assist lower that number. The Centers for Disease Control and Prevention stated that about 1.2 million people in the United States have HIV, the virus that causes AIDS, and 20% of those people are unaware they are infected.
Shifting readers focus to broader market, let’s consider market performance of other stocks that significantly affect same sector. Telefonaktiebolaget LM Ericsson (ADR) (NASDAQ:ERIC) increased +1.71% to settle at $9.24, Research In Motion Limited (USA) (NASDAQ:RIMM) moved down -1.87% to end at $7.35 while QUALCOMM, Inc. (NASDAQ:QCOM) jumped +1.07% to finish on Tuesday at $56.26.
OraSure Technologies, Inc. (NASDAQ:OSUR) last session volume of 719,000 shares was higher than its average volume of 168,429.00 shares. The stock after opening at $9.10 hit high price of $9.10 and then closed at $9.03 by scoring -1.04%.
OSUR generated revenue of 85.41 million in the following twelve months and earned -$9.49 million. The Company showed a negative -11.12% in the net profit margin and as well as in its operating margin which remained -12.29%. Company’s annual sales growth for the past five year was 3.74%.
The OSUR past twelve months price to sales ratio was 6.83 and price to cash ratio remained 25.56. As far as the returns are concern, the OSUR return on equity was recorded as -9.43% and dropped -9.19% return on investment while its return on asset stayed at -7.79%.
The stock showed weekly upbeat performance of +19.68% which was maintained for the month at +5.49%. Likewise the positive performance for the quarter was recorded as +27.23% and for the year was +35.20% while the YTD performance remained at +32.82%.
DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! QuoteDaddy.com delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with QuoteDaddy.com! CLICK HERE TO START YOUR FREE 30-DAY TRIAL
